CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 02, 2023	Jul. 03, 2022	Jul. 02, 2023	Jul. 03, 2022
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests		$ 2,338	$ 9,911	$ 7,894	$ 17,781
Foreign currency translation adjustments, net		242	(1,268)	343	(1,631)
Unrealized holding gains/(losses) on derivative financial instruments, net		109	651	112	854
Reclassification adjustments for (gains)/losses included in net income	[1]	(163)	(144)	140	(357)
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total		(54)	507	251	497
Unrealized holding gains/(losses) on available-for-sale securities, net		26	(486)	113	(620)
Reclassification adjustments for (gains)/losses included in net income	[2]	16	255	(493)	487
Other comprehensive income (loss), available-for-sale securities, before tax, total		42	(232)	(379)	(132)
Reclassification adjustments related to amortization of prior service costs and other, net		(30)	(31)	(59)	(68)
Reclassification adjustments related to curtailments of prior service costs and other, net		(7)	1	(12)	(10)
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax		(37)	(30)	(72)	(78)
Other comprehensive income/(loss), before tax		193	(1,023)	143	(1,344)
Tax provision/(benefit) on other comprehensive income/(loss)		9	(55)	(53)	(115)
Other comprehensive income/(loss) before allocation to noncontrolling interests		184	(968)	196	(1,228)
Comprehensive income/(loss) before allocation to noncontrolling interests		2,522	8,943	8,091	16,553
Less: Comprehensive income/(loss) attributable to noncontrolling interests		8	0	18	6
Comprehensive income/(loss) attributable to Pfizer Inc.		$ 2,514	$ 8,943	$ 8,072	$ 16,546

[1] Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.

[2] Reclassified into Other (income)/deductions—net.